Complete genome characterization of SARS-CoV-2 is instrumental in the understanding of the COVID-19 pandemic. The emergence of variants of concern has placed a greater importance in monitoring changes to the SARS-CoV-2 genome through NGS. Gain a deeper understanding of underlying influences affecting vaccine and therapeutic efficacy by monitoring changes in the viral genome over time with our SARS-CoV-2 viral genome assay. We utilize the Ion Ampliseq SARS-CoV-2 Research Panel, a targeted amplicon sequencing chemistry, to provide complete genome coverage and accurate variant calling at low viral loads allowing for flexibility to a range of sample types. This panel consists of 2 primer pools providing redundant coverage minimizing any potential coverage dropout as a result of mutational changes in the viral genome. Using a comprehensive data analysis solution, we are able to deliver a complete SARS-CoV-2 viral genome sequence with accurate variant calling and informed annotation.
![]() |
Nasopharyngeal Swab
|
![]() |
Viral Load Quantitation
|
![]() |
Viral RNA Isolation
|
![]() |
Ion Genestudio S5 Sequencing
|
Covers >99% of the SARS-CoV-2 genome, all serotypes included
100% Accuracy and Sensitivity for SNVs and Indels above LoD
Retroviral and lentiviral vectors are increasingly being used in the engineering of oncologic cell therapies; however, they may pose risk to human health in the event the viral vector becomes...
Genetic variation in neoplasia can take the form of single or multiple nucleotide variants, gene fusions, amplifications, and/or splice variations. This heterogeneity can pose a challenge in...
Q2 Solutions Innovation Laboratories is located in the heart of the dynamic Research Triangle Park and within our global headquarters in Durham, NC, USA. This facility creates an innovative...